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 Abstract 
Objective: To provide an estimate of the morbidity and mortality due to abdominal 
overweight and obesity in the Australian population.  
Design and Setting: Prospective, national, population-based AusDiab study. 
Patients, Participants: Men and women aged ≥25 years at study entry in 1999/2000. 
Main Outcome Measure(s): Five year follow-up (2000 to 2005) for incident health 
outcomes (type 2 diabetes, hypertension, dyslipidaemia, the metabolic syndrome and 
cardiovascular diseases) and eight year mortality follow-up. Logistic and Cox-
proportional hazards regression was used to assess risk for incident health outcomes 
and mortality among those classified as abdominally overweight or obese compared 
to those with a normal waist circumference at baseline, and across quintiles of waist 
circumference and (for mortality only) waist to hip ratio. 
Results: Abdominal obesity was associated with odds ratios of between 2 and 5 for 
incident type 2 diabetes, dyslipidaemia, hypertension and the metabolic syndrome. 
The risk of myocardial infarction among the obese was similarly increased in men 
(HR = 2.75 (95%CI 1.08-7.03)), but not women (HR=1.43 (0.37-5.5)). Abdominal 
obesity-related population attributable fractions for these outcomes ranged from 13% 
to 47% and were highest for type 2 diabetes. No significant associations were 
observed between all-cause mortality and increasing quintiles of abdominal obesity. 
Conclusions: These findings confirm the considerably heightened risk conferred by 
abdominal obesity for type 2 diabetes, the metabolic syndrome (as well as its 
components) and cardiovascular disease, and provides important information with 
which to more precisely estimate the burden of disease attributable to obesity in 
Australia. 
 
 
 
 Introduction 
Reports from the national Australian Diabetes, Obesity and Lifestyle (AusDiab) Study 
have previously been used to highlight the alarming levels of overweight and obesity 
now prevalent among adult Australians.1 Overweight and obesity are increasingly 
common2 and contribute significantly to multiple adverse health outcomes, including 
type 2 diabetes, cardiovascular diseases (CVD), the metabolic syndrome, 
hypertension and dyslipidaemia, as well as premature mortality.3-6  
An absence of country-specific relative risk data has been identified by the World 
Health Organization (WHO) as a major limitation in the preparation of accurate 
estimates of burden of disease. Follow-up of the AusDiab cohort has now allowed an 
assessment of the strength of associations between abdominal obesity and each of 
type 2 diabetes, the metabolic syndrome and its components, myocardial infarction 
and all-cause mortality among a contemporary national sample of Australian adults.  
Methods 
Survey population 
The study methods for the AusDiab study have been described in detail elsewhere.7, 8 
The AusDiab study was a nation-wide population-based stratified cluster survey of 
11247 adults (44.9% men) aged ≥25 years in 1999-2000 (response was 55.3% of 
those completing a household interview and estimated to be 37% of the eligible 
population). In 2004-2005, 60.6% of the 10788 eligible participants returned for a 
follow-up physical examination. After excluding participants aged >75 years (n=285) 
due to the established lack of association between obesity and many health outcomes 
in the elderly,9 as well as pregnant women (n=42), 6072 participants (54.7% women) 
were available for analysis of incident diabetes, metabolic syndrome and its 
components.10 Responders to the follow-up physical examination were more likely 
than non-responders to be non-smokers, tertiary educated, married and speak English 
at home.8 
Survey methods 
Waist circumference was measured twice, halfway between the lower border of the 
ribs and the iliac crest on a horizontal plane. If measurements varied by >2 cm, a third 
was taken. The mean of the two closest measurements was calculated. A 75g oral 
glucose tolerance test (OGTT) was conducted at baseline and follow-up surveys in all 
non-pregnant participants not using insulin or taking oral hypoglycaemic drugs. 
Biochemical parameters, height, weight and blood pressure were measured as 
previously described.8  
Diabetes was classified according to WHO criteria11, 12 and the metabolic syndrome 
defined according to the International Diabetes Federation (IDF) definition.13 
Hypertension and cut-points for elevated triglycerides and low high-density 
lipoprotein cholesterol (HDL-C) were as described in the IDF definition of the 
metabolic syndrome. WHO waist circumference cut-points representing “increased” 
and “substantially increased” risk of obesity-associated metabolic complications in 
Europids were used to represent “overweight” (men 94cm; women 80cm) and 
“obesity” (men 102cm; women 88cm) respectively.14 One week recall of leisure-time 
physical activity was assessed via the interviewer-administered Active Australia 
questionnaire, previously shown to have good test-retest reliability.15, 16 Self-reported 
television viewing time over the previous week, smoking status and highest level of 
education achieved were assessed by interviewer-administered questionnaire.  
Myocardial infarction and mortality follow-up 
Of the 10242 eligible participants aged <75 years at baseline, 8396 completed an 
interviewer-administered CVD history questionnaire at the 2004-2005 physical 
examination, or by telephone. Those who did not consent to medical record 
adjudication or without complete myocardial infarction data (n=14) were excluded, 
leaving 8382 (81.8% of those eligible) available for analysis of incident myocardial 
infarction. Average follow-up time for myocardial infarction was 60.8 months, with 
45 non-fatal events occurring during the follow-up period. 
Incident myocardial infarction was ascertained by physician adjudication of medical 
records according to WHO/MONICA criteria for myocardial infarction17, as 
previously described.18 These methods have been validated against a hospital 
morbidity database. 18 
Death was ascertained by linking the AusDiab cohort to the Australian National Death 
Index (NDI), as described previously.19 The accuracy of the NDI for ascertainment of 
vital status has been established.20 The follow-up period for all-cause mortality was to 
the date of death or April 30, 2008, whichever occurred first. All those who died 
within two years of the baseline survey were excluded (n=107). Average mortality 
follow-up was 95.8 months, with 316 deaths occurring during the follow-up period.  
AusDiab survey protocols were approved by the ethics committee of the International 
Diabetes Institute, Monash University’s Standing Committee on Ethics in Research 
involving Humans and the Australian Institute of Health and Welfare. Informed 
consent was obtained from all participants. 
Statistical methods 
To test for linear trends in means and linear associations in proportions of baseline 
characteristics among normal, overweight and obese groups, one-way ANOVA (with 
a linear polynomial term) and chi-square tests for linear trend were used, respectively. 
Age-adjusted logistic regression was used to calculate odds ratios (OR) for incident 
diabetes, elevated triglycerides, hypertension, metabolic syndrome and reduced HDL-
C, comparing those classified at baseline as overweight and obese with normal, and 
for quintiles of waist circumference. The population attributable fraction (AFp), was 
calculated for each gender using the following formula:21  
AFp = p(RR-1)/p(RR-1)+1 
where p is the gender-specific proportion of obesity in the baseline AusDiab cohort1. 
Risk ratios (RR) were estimated from the calculated odds and hazard ratios (HR) for 
incident events using the method of Zhang and Yu22. Cox proportional hazard models 
were used to estimate all-cause mortality HR for quintiles of waist circumference and 
waist to hip ratio (included because it was shown in two other Australian cohorts to be 
more strongly associated with mortality than was waist circumference)23, 24 and to 
estimate HR for myocardial infarction among those classified as overweight or obese 
compared to normal. For mortality analyses, the lowest adjusted risk for mortality was 
observed in the second quintile for waist to hip ratio. This group was therefore chosen 
as the reference group, with the higher mortality risk in the first quintile most likely 
due to weight-loss inducing conditions such as respiratory diseases and cancer. 
Proportionality of hazards was assessed with log-log plots of the relative hazards by 
time and Kaplan Meier plots of the observed versus predicted survival curves using 
Stata 10 (StataCorp, College Station, Texas, USA). All other analyses were conducted 
with SPSS 15.0 (SPSS Inc., Chicago IL, USA).  
Results 
Risk related to categories of abdominal obesity 
Baseline physiological and demographic characteristics of the cohort stratified by 
baseline waist circumference categories are presented in Table 1. Strong linear 
associations (p<0.0001) were seen between abdominal obesity and education, 
physical activity, television viewing, all lipid, glucose and blood pressure parameters, 
type 2 diabetes, the metabolic syndrome and history of CVD in both men and women.  
Abdominal obesity-related adjusted ORs for the development of various clinical 
outcomes are shown in Figure 1. Among those classified as obese, compared to those 
with a normal waist circumference, the risk of type 2 diabetes, dyslipidaemia, 
hypertension and the metabolic syndrome was increased by between 2 to 5 times in 
women and men. The risk of myocardial infarction was similarly increased in men 
(HR = 2.75 (95%CI 1.08 – 7.03), p=0.035), but not women (HR=1.43 (95%CI 0.37 – 
5.5), p>0.05). Those with waist circumference in the overweight range were at 
increased risk of the metabolic syndrome and its three components (hypertension, 
elevated triglycerides and low HDL-C). Risk for type 2 diabetes in men only, and 
myocardial infarction in women only was increased in the overweight, however this 
did not reach statistical significance. Since a larger cohort was available for analysis 
of myocardial infarction than other outcomes, we repeated this analysis after 
excluding those who only participated in the phone based follow-up of myocardial 
infarction (n=2069; 13/45 myocardial infarction events). HRs for overweight and 
obesity were 1.77 (0.3-10.6) and 2.06 (0.4-9.9) in women and 0.7(0.2-2.6) and 1.9 
(0.7-5.1) in men (all p>0.05).  
Risk over the range of waist circumference 
To assess risk over the continuum of waist circumference, odds ratios for incident 
type 2 diabetes, the metabolic syndrome, hypertension and dyslipidaemia were plotted 
against quintiles of waist circumference. Myocardial infarction was not included 
because of the small number of cases in each gender-specific waist quintile. Increases 
in risk begin below the cut-point for overweight (Figure 2), with statistically 
significant increases in the odds of all outcomes in men, and elevated triglycerides, 
reduced HDL-C and the metabolic syndrome in women being observed by the second 
quintile of waist circumference (73.7-80.3cm in women; 88.2-94.2cm in men).  
Mortality risk related to abdominal obesity 
HRs for all-cause mortality over eight years of follow-up were plotted against 
quintiles of waist circumference and waist to hip ratio, adjusted for age, history of 
CVD, non-skin cancer and smoking status (Figure 3). Even though a weak J-shaped 
relationship between increasing levels of obesity and mortality was evident for waist 
to hip ratio in women, this did not reach statistical significance in any quintile. No 
trend of increasing risk of death with increasing obesity was evident for waist 
circumference in women, or either measure in men. Similar results were obtained 
after excluding smokers and those reporting a history of CVD or cancer; or when 
deaths in only the first year (rather than two years) of follow-up were excluded or 
when no deaths were excluded. 
Obesity-related population attributable fraction 
The obesity-related population attributable fraction was estimated for each non-fatal 
outcome. This was highest for type 2 diabetes (47.4% in men, 38% in women), 
similar for elevated triglycerides, reduced HDL-C and hypertension (all >30% in 
women and around 17% in men), and for myocardial infarction was higher in men 
compared with women (31.9% vs. 12.8%).  
[Note: Results for Figure 1, as well as the risk per unit of BMI and per cm of waist 
circumference, are provided in tabular form as an online appendix] 
Discussion 
These findings provide further evidence of the serious negative health effects 
resulting from the high and increasing rates of overweight and obesity in Australia. 
Previous reports from the AusDiab study revealed that in 2000, 60% of adult 
Australians were overweight or obese1, with the prevalence of obesity in Australia 
among the highest of any developed country.25 Follow-up of the AusDiab cohort has 
now allowed us to report on the impact of what has been described as an obesity 
epidemic. The results presented here confirm that abdominal overweight, and more 
particularly obesity, are significant risk factors for multiple negative health outcomes, 
and demonstrate the serious health consequences of the obesogenic environment in 
which we live.  
We could not fully cover the spectrum of ill-health associated with obesity, with 
several conditions including osteoarthritis, cancers, chronic obstructive pulmonary 
disease (COPD), gall bladder disease, sleep apnoea and depression not assessed in the 
AusDiab study.6, 26  We do however include four of the top five conditions for which 
obesity resulted in disability adjusted life years lost in the 1996 Australian Burden of 
Disease Study.27 Indeed, CVD, hypertension and type 2 diabetes were responsible for 
68% of the obesity-related burden of disease. A recent report estimated the annual 
direct and indirect financial costs of obesity in Australia to be AUD$3.8 billion, with 
over half of this borne by Government and society.28  
A WHO report into the consequences of obesity highlighted a lack of relative risk 
data as a major evidence gap preventing more accurate burden of disease estimates.26 
Obesity-related risk is related to the demographic, behavioural and biomedical risk 
factor profile of the population, which differs between countries and over time. It is 
therefore difficult to extrapolate estimates from other populations to the Australian 
situation. The results presented here help to address this identified evidence gap, and 
are the first estimates of obesity-related relative risk for these conditions from a 
national Australian sample. Furthermore, they provide valuable evidence with which 
to more precisely calculate the total economic and health burden attributable to 
obesity , and to inform initiatives for addressing the already high levels of obesity 
present in Australia. 
The population attributable fraction estimates presented require careful interpretation. 
These figures effectively compare the incidence observed in the AusDiab sample with 
a hypothetical population in which obesity is totally absent. Since no intervention 
currently exists to eliminate obesity, they must be thought of as purely theoretical.29 
Indeed, national obesity rates have not fallen through the use of targeted interventions 
in any country.30 A more detailed case study of the impact of obesity reduction 
interventions is obviously required. The risk estimates presented here will help to 
inform such endeavours in the Australian context. 
Although body mass index (BMI) is the most frequently reported index of obesity, 
and a measure routinely used in WHO obesity surveillance initiatives, the recently 
announced Australian national obesity campaign (“Measure Up”) is based on the 
promotion of waist circumference measurement to identify obesity.31 Waist 
circumference is easily measured and has been shown to be both a better indicator of 
abdominal adiposity as well as a stronger predictor of many health outcomes than is 
BMI.5, 26, 32 Evidence based cut-points for waist-circumference in different ethnic 
groups are lacking, and therefore those used in this report are appropriate only for 
Europid populations. For comparative purposes, analyses using BMI to categorize 
obesity are presented in an online appendix. Waist to hip ratio has been included in 
the analysis of mortality because it has been shown in two other population-based 
Australian cohorts to be more closely associated with mortality than was waist 
circumference.23, 24 This trend was also present in the AusDiab cohort, even though 
the increased hazard ratios did not reach statistical significance, most likely due to a 
follow-up period of only eight years.  
It is important to interpret this work in the context of the inherent limitations of the 
survey. Firstly, the risks associated with lesser degrees of overweight and obesity, 
particularly for myocardial infarction and mortality, may not become apparent 
without considerably longer follow-up than the five years (and eight years for 
mortality) used here. Other appropriately conducted and analysed studies with longer 
follow-up and more deaths have shown a strong and independent relationship between 
abdominal obesity and mortality.24, 33, 34 Secondly, non-response to the baseline and 
follow-up surveys means that the results are from a population-based, but not 
necessarily representative sample of Australians. Finally, due to small numbers of 
indigenous Australians in the sample, obesity-related risks for this population cannot 
be estimated.  
Previous reports from AusDiab have demonstrated strong associations between 
abdominal obesity and time spent in both physical activity and television viewing1, as 
well as the effects of these behaviours and sedentary time on markers of cardio-
metabolic risk.35-37 To address the obesity epidemic will require environmental and 
policy initiatives that provide realistic and achievable opportunities for Australians to 
be more active, to avoid too much time spent sitting and to avoid obesogenic food 
environments.38 A recent report from the Obesity Working Group of the Australian 
National Preventative Health Taskforce has highlighted the multi-sectoral approach 
required to achieve the goal of preventing unhealthy weight gain in Australia.30  
Conclusions 
Follow up of the AusDiab cohort over five years has allowed us to simultaneously 
assess the impact of obesity on multiple health outcomes in adult Australians. We 
have confirmed here the considerably heightened risk for type 2 diabetes, the 
metabolic syndrome, hypertension, dyslipidaemia and CVD associated with 
abdominal obesity. This work now allows more precise estimation of the total 
financial and health burden attributable to obesity in Australia, and more accurate 
assessment of the impact of obesity prevention initiatives. Furthermore, it provides 
evidence with which to advocate for the environmental, policy and behavioural 
changes required to address obesity in this country. 
Table 1: Cross-sectional associations of health and demographic characteristics with gender and waist circumference categories at baseline among 
non-pregnant adults aged <75 years who attended both baseline (1999-2000) and follow-up (2004-2005) AusDiab surveys and had waist 
circumference data. 
 
    Waist category 
    Women Men 
 All Women Men 
Normal 
(<80cm) 
Overweight 
(80-88cm) 
Obese 
(>88cm) 
Normal 
(<94cm) 
Overweight 
(94-102cm) 
Obese 
(>102cm) 
n 6072 3321 2751 1336 783 1202 1100 794 857 
Age (years) 50.5 (11.7) 50.3 (11.7) 50.9 (11.8) 46.9 (11.5) 51 (11.2) 53.6 (11.3)† 48 (11.8) 52.3 (11.4) 53.2 (11.2)† 
BMI (kg/m2) 26.9 (4.9) 26.7 (5.5) 27.2 (4) 22.5 (2.3) 26 (2.4) 31.9 (5.1)† 24.1 (2.2) 27 (2) 31.3 (3.5)† 
Weight (kg) 76.9 (16) 70.7 (14.9) 84.4 (13.9) 59.4 (6.9) 68.8 (6.8) 84.5 (13.9)† 74 (8.1) 83.8 (7.4) 98.2 (12.5)† 
Waist circumference (cm) 90.5 (13.8) 84.9 (13.3) 97.2 (11.1) 72.8 (4.6) 83.8 (2.3) 99.2 (9.5)† 87 (5.2) 97.6 (2.2) 110.1 (7.5)† 
Hip circumference (cm) 104.8 (9.8) 105.3 (11.3) 104.3 (7.5) 96.8 (5.8) 104.1 (5.5) 115.4 (10.7)† 98.8 (4.7) 104.2 (4.1) 111.3 (6.8)† 
Serum HDL-C (mmol/L) 1.4 (0.4) 1.6 (0.4) 1.3 (0.3) 1.7 (0.4) 1.6 (0.4) 1.4 (0.3)† 1.4 (0.3) 1.2 (0.3) 1.1 (0.3)† 
Serum triglycerides (mmol/L)1 1.3 (1.8) 1.2 (1.7) 1.4 (1.8) 0.9 (1.6) 1.2 (1.6) 1.6 (1.7)† 1.2 (1.7) 1.5 (1.7) 1.8 (1.7)† 
Fasting plasma glucose (mmol/L)1 5.5 (1.2) 5.3 (1.2) 5.7 (1.2) 5.1 (1.1) 5.3 (1.1) 5.7 (1.2)† 5.5 (1.1) 5.6 (1.1) 5.9 (1.2)† 
2hr plasma glucose (mmol/L)1 5.9 (1.4) 5.9 (1.3) 5.8 (1.4) 5.3 (1.3) 5.9 (1.3) 6.7 (1.4)† 5.4 (1.4) 5.8 (1.4) 6.4 (1.4)† 
Metabolic syndrome (IDF definition %) 33 27.9 39.2 0 28.1 59.3† 0.8 55 74.1† 
Diabetes (%)2 6.5 5.4 7.7 1.4 2.7 12.1† 3.7 6.3 14.8† 
Hypertension (%)3 29.6 26.7 33.1 12.9 25.3 43.1† 20.9 34.8 46.7† 
Systolic blood pressure (mmHg) 128.1 (17.4) 125.2 (17.8) 131.7 (16.1) 118.5 (15.4) 125.7 (16.7) 132.3 (18.2)† 127.2 (15.2) 132.8 (15.9) 136.4 (16)† 
Diastolic blood pressure (mmHg) 70.3 (11.6) 66.5 (10.9) 74.9 (10.7) 64.2 (10.4) 66.7 (10.1) 69 (11.4)† 72 (10.4) 75.5 (10.6) 78 (10.1)† 
Previous CVD4 6.2 4.4 8.4 2.8 2.2 7.6† 5 9.3 11.7† 
Current smoker (%) 11.9 10.4 13.8 10.8 8.9 11 14.3 13.5 13.2 
Tertiary education (%)5 41.6 37.2 46.8 43.8 35.6 30.9† 53.3 44.8 40.6† 
TV viewing (hours/wk) 12.5 (9.2) 11.8 (9) 13.3 (9.4) 10.2 (8) 11.6 (9) 13.7 (9.5)† 12 (8.9) 13.1 (8.6) 15 (10.5)† 
Physical activity (hours/wk) 4.7 (5.5) 4 (4.9) 5.5 (6.1) 4.6 (5.2) 4.1 (5) 3.3 (4.4)† 6.4 (6.6) 5.2 (5.6) 4.8 (5.9)† 
 
Data are:   
1Geometric mean and standard deviation 
2 Diabetes based on WHO criteria, includes previously and newly diagnosed diabetes, excludes type 1 diabetes 
3 Hypertension defined as blood pressure greater than 130/85mmHg or on medication for hypertension 
4 Previous cardiovascular disease (CVD) includes self-reported stroke, heart attack or angina 
5 Higher education defined as education beyond high school (university or technical and further education) 
† p<0.0001 (test for linear trend) 
Table 2. Estimated fraction of incident outcomes that would not have occurred in 
the AusDiab population if no obesity was present (Population Attributable 
Fraction, AFp). 
 
 
Estimated RR† AFp 
 Women Men Women Men 
Type 2 Diabetes 3.6 3.3 47.4 38.0 
Elevated triglycerides 3.2 1.7 43.1 16.7 
Reduced HDL 2.3 1.8 30.3 17.5 
Hypertension 2.6 1.8 35.5 17.0 
Myocardial infarction 1.4 2.7 12.8 31.9 
 
† Risk ratio (RR) estimated from observed odds ratios and hazard ratios (Figure 1) using the 
method of Zhang and Yu.22 These are presented because the calculation of AFp is based on 
RR, not odds or hazard ratios.21 
Cut points: HDL-C <1.0 mmol/l (M), <1.3 mmol/l (F); Triglycerides ≥1.7 mmol/l; 
Hypertension defined as ≥140/90 mmHg or reporting antihypertensive use.  
HDL-C – high density lipoprotein cholesterol.  
 
 
Figure 1. Gender-specific, adjusted odds/hazard ratios† among Australian adults 
aged 25 to 75 years for the development of various clinical outcomes over five 
years in those classified as obese and overweight using waist circumference at 
baseline, compared to those with a normal waist circumference at baseline.  
 
†Odds ratios for all outcomes, with the exception of myocardial infarction for which hazard 
ratios are reported. Analysis adjusted for age and smoking status (current or ex/never), and in 
the case of myocardial infarction, self-reported history of cardiovascular disease. 
‡Metabolic Syndrome defined as ≥2 of the non-obesity components of the International 
Diabetes Federation definition.13  
Cut points: HDL <1.0 mmol/l (M), <1.3 mmol/l (F); Triglycerides ≥1.7mmol/l; Hypertension 
defined as ≥140/90 mmHg or reporting antihypertensive use.  
HDL – high density lipoprotein cholesterol.  
Figure 2. Gender-specific, adjusted odds ratios† for the development of various 
clinical outcomes and biomedical markers of cardiometabolic risk over five years 
by quintiles of waist circumference‡ at baseline among Australian adults aged 25 
to 75 years. 
 
†Analysis adjusted for age and smoking status (current or ex/never).  
‡Quintiles of waist circumference (cm.) – Women: 1 (<73.7); 2 (73.7-80.3); 3 (80.4-87.0); 4 
(87.1-96.2); 5 (>96.2). Men: 1 (<88.2); 2 (88.2-94.2); 3 (94.3-99.3); 4 (99.4-106.2); 5 
(>106.2). 
Cut points: HDL <1.0 mmol/l (M), <1.3 mmol/l (F); Triglycerides ≥1.7mmol/l; Hypertension 
defined as ≥140/90 mmHg or reporting antihypertensive use. Metabolic Syndrome defined as 
≥2 of the non-obesity components of the International Diabetes Federation definition.13  
HDL – high density lipoprotein cholesterol. 
Figure 3. Adjusted hazard ratios and 95% confidence intervals† for all-cause 
mortality over eight years according to quintiles of baseline waist to hip ratio 
and waist circumference in Australian adults aged 25 to 75 years. 
 
†Adjusted for age, self-reported history of cardiovascular disease (either angina, myocardial 
infarction or stroke), self-reported cancer (excluding skin cancer) and smoking status (current 
smoker vs. ex/never smoker). Those who died within two years of attending the baseline 
survey excluded from analysis. 
‡Quintiles of waist circumference (cm.) – Women: 1 (<73.7); 2 (73.7-80.3); 3 (80.4-87.0); 4 
(87.1-96.2); 5 (>96.2). Men: 1 (<88.2); 2 (88.2-94.2); 3 (94.3-99.3); 4 (99.4-106.2); 5 
(>106.2). Quintiles of waist to hip ratio – Women: 1 (<0.75); 2 (0.75-0.79); 3 (0.80-0.82); 4 
(0.83-0.87); 5 (>0.87). Men: 1 (<0.88); 2 (0.88-0.91); 3 (0.92-0.95); 4 (0.96-0.99); 5 (>0.99). 
Appendix 1. Gender-specific, adjusted odds/hazard ratios† among Australian 
adults aged 25 to 75 years for the development of various clinical outcomes over 
five years in those classified as obese and overweight at baseline compared to 
those who at baseline had a normal waist circumference and BMI respectively, 
and per unit of BMI or per cm. of waist circumference. [To be published online 
only] 
  
OR/HR for overweight and obese compared to normal, and per cm. of waist 
circumference or per unit of BMI 
  
Waist circumference BMI 
    Men Women Men Women 
Diabetes                                           
Overweight 1.7 (0.9,3.0) 0.9 (0.4,1.8) 2.1 (1.1,3.8) 1.6 (1.0,2.8) 
Obese 3.5 (2.1,5.9) 3.8 (2.3,6.3) 5.1 (2.8,9.5) 3.6 (2.2,6.0) 
Per cm/BMI unit 1.06 (1.04,1.08) 1.05 (1.03,1.06) 1.17 (1.12,1.23) 1.11 (1.07,1.14) 
Elevated 
triglycerides                             
Overweight 2.3 (1.7,3.1) 2.2 (1.6,3.1) 2.3 (1.7,3.0) 2.9 (2.1,3.9) 
Obese 2.1 (1.5,2.8) 4.0 (3.0,5.4) 2.4 (1.7,3.5) 3.6 (2.6,5.0) 
Per cm/BMI unit 1.03 (1.02,1.04) 1.05 (1.04,1.05) 1.08 (1.05,1.11) 1.09 (1.07,1.11) 
Hypertension                                       
Overweight 1.6 (1.1,2.1) 1.9 (1.4,2.7) 1.5 (1.1,2.1) 2.1 (1.6,2.8) 
Obese 2.1 (1.5,3.0) 3.3 (2.4,4.4) 3.5 (2.3,5.2) 4.4 (3.1,6.2) 
Per cm/BMI unit 1.04 (1.02,1.05) 1.04 (1.03,1.05) 1.12 (1.07,1.16) 1.11 (1.09,1.14) 
Metabolic 
Syndrome                                 
Overweight 2.6 (1.9,3.6) 2.4 (1.7,3.3) 2.2 (1.6,2.9) 2.6 (1.9,3.5) 
Obese 3.0 (2.1,4.3) 4.7 (3.5,6.4) 4.0 (2.6,6.0) 4.4 (3.2,6.2) 
Per cm/BMI unit 1.05 (1.04,1.07) 1.06 (1.05,1.07) 1.14 (1.10,1.19) 1.13 (1.10,1.16) 
Reduced 
HDL                                        
Overweight 1.7 (1.3,2.5) 1.8 (1.3,2.5) 2.0 (1.4,2.7) 1.6 (1.2,2.2) 
Obese 2.0 (1.4,2.7) 2.6 (1.9,3.6) 1.9 (1.3,2.9) 2.0 (1.4,2.8) 
Per cm/BMI unit 1.02 (1.01,1.04) 1.03 (1.02,1.04) 1.06 (1.03,1.1) 1.07 (1.04,1.09) 
Myocardial 
Infarction                              
Overweight 1.1 (0.4,3.4) 1.5 (0.3,6.6) 2.9 (0.8,9.9) 1.8 (0.5,7.3) 
Obese 2.8 (1.1,7.0) 1.4 (0.4,5.5) 4.7 (1.3,17.1) 2.5 (0.6,9.9) 
Per cm/BMI unit 1.03 (1.00,1.06) 1.04 (1.00,1.07) 1.10 (1.02,1.18) 1.07 (0.99,1.16) 
 
†Odds ratios for all outcomes, with the exception of myocardial infarction for which hazard 
ratios are reported. Analysis adjusted for age and smoking status (current or ex/never), and in 
the case of myocardial infarction, self-reported history of cardiovascular disease. 
‡Metabolic Syndrome defined as ≥2 of the non-obesity components of the International 
Diabetes Federation definition.13  
Cut points: HDL <1.0 mmol/l (M), <1.3 mmol/l (F); Triglycerides ≥1.7mmol/l; Hypertension 
defined as ≥130/85 mmHg or reporting antihypertensive use.  
HDL-C – high density lipoprotein cholesterol.  
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